Literature DB >> 10964537

Inhibition of murine macrophage IL-12 production by natural and synthetic DNA.

D S Pisetsky1, C F Reich.   

Abstract

DNA is a complex macromolecule whose immunological properties vary with sequence and structure. To determine whether DNA can inhibit immune responses, the effects of mammalian DNA and synthetic phosphodiester (Po) and phosphorothioate (Ps) oligonucleotides (ODNs) on IL-12 production were tested using murine macrophages. With bacterial DNA as a stimulant, calf thymus DNA and human placenta DNA blocked IL-12 production by splenic and bone marrow macrophages. A (dG)(30) Po ODN and all single-base Ps 30 mer ODNs were also effective inhibitors. The Ps ODNs also blocked IL-12 production induced by lipopolysaccharide (LPS) and a stimulatory Ps ODN. With the J774 cell line, single-base Ps ODNs inhibited IL-12 production induced by bacterial DNA, LPS, and a stimulatory Ps ODN. Together, these results indicate that DNA has inhibitory properties, suggesting that mammalian DNA could limit immune activation during inflammation and counteract the effects of bacterial DNA. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10964537     DOI: 10.1006/clim.2000.4897

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  26 in total

Review 1.  Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus.

Authors:  P Lenert
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

2.  Inhibition of a C-rich oligodeoxynucleotide on activation of immune cells in vitro and enhancement of antibody response in mice.

Authors:  Guang Yang; Min Wan; Yongsheng Zhang; Luguo Sun; Ran Sun; Dali Hu; Xiaojing Zhou; Li Wang; Xiuli Wu; Liying Wang; Yongli Yu
Journal:  Immunology       Date:  2010-12       Impact factor: 7.397

3.  Impact of site-specific nucleobase deletions on the arthritogenicity of DNA.

Authors:  Jan L Bjersing; Andrej Tarkowski; Ekambar R Kandimalla; Helen Karlsson; Sudhir Agrawal; L Vincent Collins
Journal:  Inflammation       Date:  2004-06       Impact factor: 4.092

Review 4.  Synthetic oligonucleotides as modulators of inflammation.

Authors:  Dennis Klinman; Hidekazu Shirota; Debra Tross; Takashi Sato; Sven Klaschik
Journal:  J Leukoc Biol       Date:  2008-04-22       Impact factor: 4.962

5.  Suppressive oligodeoxynucleotides promote the generation of regulatory T cells by inhibiting STAT1 phosphorylation.

Authors:  Christian Bode; Jing Wang; Dennis M Klinman
Journal:  Int Immunopharmacol       Date:  2014-10-12       Impact factor: 4.932

6.  Suppressive oligonucleotides inhibit inflammation in a murine model of mechanical ventilator induced lung injury.

Authors:  Julia Scheiermann; Dennis M Klinman
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

Review 7.  Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases?

Authors:  P Lenert
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

8.  Treg-inducing capacity of genomic DNA of Bifidobacterium longum subsp. infantis.

Authors:  Dongmei Li; Jie Cheng; Ziang Zhu; Marta Catalfamo; David Goerlitz; Oliver J Lawless; Luke Tallon; Lisa Sadzewicz; Richard Calderone; Joseph A Bellanti
Journal:  Allergy Asthma Proc       Date:  2020-09-01       Impact factor: 2.587

Review 9.  Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9.

Authors:  Petar S Lenert
Journal:  Mediators Inflamm       Date:  2010-05-18       Impact factor: 4.711

10.  DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-cell and dendritic cell activation in vitro and autoantibody production in lupus-prone MRL-Fas(lpr/lpr) mice in vivo.

Authors:  Petar Lenert; Kei Yasuda; Liliana Busconi; Patrice Nelson; Courtney Fleenor; Radhika S Ratnabalasuriar; Peter L Nagy; Robert F Ashman; Ian R Rifkin; Ann Marshak-Rothstein
Journal:  Arthritis Res Ther       Date:  2009-05-28       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.